Novel self-closing 12F mitral valve repair system to percutaneously treat moderate to severe regurgitation using transcatheter edge-to-edge repair (teer) technique via femoral vein access

Ended Project Grant Awarded Last action

Award ID
SB1HL174244
Recipient
Awarding agency
Obligated
$770,355

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Place of performance
Newark, CA 94560, USA

Award details come from USAspending.gov.

Description

Abstract
The medfree® valve repair system will innovatively improve upon the current market leading mitraclip device, while leveraging and building on the proven transcatheter edge-to-edge repair technique. We aim to address this vastly unmet percutaneous structural heart market by delivering a simpler, easier-to-use device in a smaller 12F catheter system that can be used by a single operator. Medfree has already completed preclinical GLP studies in porcine model (cohort a: n=2, 30 days; cohort b: n=5, 140 days) with outstanding results. MRI and durability (fatigue) studies were also completed with outstanding results. We are now seeking funds via NIH commercialization readiness program, in preparation for EFS/FIH clinical studies.

Transactions

Action Obligated Date
Amendment $0
Amendment $219,295
Amendment $275,530
Original award $275,530

Quick answers

Who received award SB1HL174244?

SB1HL174244 was awarded to Medfree Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on April 1, 2024.

How much is award SB1HL174244 worth?

$770,355 has been obligated on SB1HL174244.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award